Latest Interferon beta-1a Stories
ROCKLAND, Mass. and NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- EMD Serono, Inc. and Pfizer Inc.
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
EXTON, Pa., April 26 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis.
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent.
ROCKLAND, Mass., Jan.
EXTON, Pa., Jan. 11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(Â®): EXTAVIA report. The survey was completed by U.S.
ROCKLAND, Mass., Dec.
ROCKLAND, Mass., Nov.
ROCKLAND, Mass., Oct. 19 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, marked the expansion of its research facility in Billerica, MA today, with a topping off ceremony.
ROCKLAND, Mass., Oct. 5 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers. EMD Serono's ranking improved to No. 6 this year, up from No.